Torrent Pharmaceuticals has announced that the US Food and Drug Administration (USFDA) has successfully completed an inspection of its Active Pharmaceutical Ingredient (API) manufacturing facility located in Vizag, Andhra Pradesh.  

The inspection, which took place from July 28 to August 1, 2025, concluded with zero observations —the company said in an exchange filing.

The Vizag plant, acquired from Glochem Industries in 2016, is a multi-product facility, with a capacity to manufacture advance intermediates and APIs. It enabled Torrent in backward integration and scale up their manufacturing capacity to meet the growing demand from the international markets.

The facility spans over 21,000 square meters and includes a built-up area of 11,361 square meters, with a manufacturing capacity of 25 metric tonnes.

Torrent Pharma, the flagship company of the Torrent Group, is a prominent player in the India pharmaceutical industry, ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), and women’s healthcare (WHC) segments. It also has a strong presence in diabetology, pain management, oncology, gynaecology, and anti-infective therapies.

Torrent Pharma's competitive edge lies in its world-class manufacturing facilities, advanced R and D capabilities, extensive domestic network, and strong global footprint spanning over 50 countries.